Key Points
- Director Christopher Starr sold 8,400 Monopar Therapeutics shares at an average price of $78.50, generating $659,400. The Rule 10b5-1 transaction reduced his holdings by 61.89% to 5,173 shares.
- Monopar shares opened at $78.29, with a market capitalization of approximately $525 million and a 52-week trading range of $50.07 to $124.82. The company reported a quarterly loss of $0.62 per share, slightly better than analyst expectations.
- Analysts maintain a generally positive outlook, with an average “Moderate Buy” rating and a $122 price target. Price targets from several firms range from $125 to $133, although one analyst downgraded the stock to “Hold.”
Monopar Therapeutics Inc. (NASDAQ:MNPR - Get Free Report) Director Christopher Starr sold 8,400 shares of the company's stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $78.50, for a total value of $659,400.00. Following the transaction, the director owned 5,173 shares of the company's stock, valued at approximately $406,080.50. This represents a 61.89% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Monopar Therapeutics Price Performance
Shares of NASDAQ MNPR opened at $78.29 on Tuesday. Monopar Therapeutics Inc. has a 1 year low of $50.07 and a 1 year high of $124.82. The stock has a market capitalization of $525.33 million, a P/E ratio of -36.08 and a beta of 1.50. The company's 50-day moving average is $106.61 and its 200 day moving average is $83.01.
Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($0.62) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.64) by $0.02. Research analysts anticipate that Monopar Therapeutics Inc. will post -2.98 earnings per share for the current year.
Wall Street Analysts Forecast Growth
Several equities research analysts recently weighed in on MNPR shares. BTIG Research raised their price target on shares of Monopar Therapeutics from $117.00 to $133.00 and gave the company a "buy" rating in a research report on Wednesday, August 12th. Zacks Research cut Monopar Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Thursday, August 13th. Wall Street Zen upgraded Monopar Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, September 12th. UBS Group set a $125.00 price target on Monopar Therapeutics in a report on Thursday, July 23rd. Finally, Morgan Stanley reaffirmed an "overweight" rating and set a $130.00 price objective on shares of Monopar Therapeutics in a research report on Monday, August 17th. Two research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $122.00.
View Our Latest Stock Analysis on Monopar Therapeutics
Institutional Investors Weigh In On Monopar Therapeutics
A number of hedge funds have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp purchased a new position in shares of Monopar Therapeutics in the 2nd quarter worth $7,124,000. Bank of America Corp DE increased its position in Monopar Therapeutics by 838.2% during the first quarter. Bank of America Corp DE now owns 59,699 shares of the company's stock valued at $3,271,000 after acquiring an additional 53,336 shares during the last quarter. ADAR1 Capital Management LLC increased its position in Monopar Therapeutics by 13.0% during the first quarter. ADAR1 Capital Management LLC now owns 264,278 shares of the company's stock valued at $14,480,000 after acquiring an additional 30,370 shares during the last quarter. The Manufacturers Life Insurance Company bought a new position in Monopar Therapeutics in the first quarter valued at about $250,000. Finally, Siren L.L.C. boosted its position in Monopar Therapeutics by 27.2% in the first quarter. Siren L.L.C. now owns 270,118 shares of the company's stock worth $14,800,000 after purchasing an additional 57,820 shares during the last quarter. 1.83% of the stock is currently owned by hedge funds and other institutional investors.
Monopar Therapeutics Company Profile
(
Get Free Report)
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments and diagnostic agents for cancer. The company's research programs are designed to address serious diseases by using targeted approaches intended to improve the effectiveness and tolerability of oncology therapies.
Monopar's portfolio has included camsirubicin, a next-generation anthracycline being developed for patients with advanced soft tissue sarcoma. The company has also developed MNPR-101, a therapeutic and imaging platform directed at the urokinase plasminogen activator receptor (uPAR), a protein associated with various aggressive cancers.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
